Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Status:	Completed
Conditions:	Neurology, Orthopedic, Women's Studies
Therapuetic Areas:	Neurology, Orthopedics / Podiatry, Reproductive
Healthy:	No
Age Range:	18 - Any
Updated:	2/10/2019
Start Date:	February 2006
End Date:	January 2008

A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia

The aim of this study is to assess longer term safety and effectiveness of Dysport®.

Inclusion Criteria:

- Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up
to Week 12, or up to Week 4 in the event of an early withdrawal

- Returned to pre-treatment status as judged by the Investigator

Exclusion Criteria:

- Pure anterocollis or pure retrocollis

- Known antibodies to botulinum toxin type A

- Requirement for botulinum toxin injections to site(s) other than the neck and unable
to avoid such treatment for the duration of the study

- Known significant underlying swallowing or respiratory abnormality which might be
exacerbated by botulinum toxin treatment

We found this trial at

sites

Allegheny General Hospital

320 E North Ave
Pittsburgh, Pennsylvania 15212

(412) 359-3131